Blechman Foundation-funded study published in Science Translational Medicine
In June 2016, researchers at the University of Pittsburgh School of Medicine announced a major breakthrough from a study, funded in part by the Blechman Foundation, that explains why the Parkinson’s-related protein alpha-synuclein is toxic to neurons in the brain. The findings offer promise to identify new therapies that could slow or stop the progression of the degenerative illness, and were published in Science Translational Medicine (“a-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease”).
You can read the full text of the journal article below and the abstract here. For more information, please see the official press release and additional coverage from NPR and Altmetric.
